Kemp Proteins and Onecyte are excited to announce a strategic partnership, bringing together our complementary strengths to redefine cell line development for next-generation biologics.

By integrating predictive, in silico molecular design with high-throughput, high-resolution single-cell analysis, this collaboration addresses the industry’s toughest challenges: long development timelines, low yields, and the complexity of emerging therapeutic formats. The combined workflow leverages Kemp’s PROTiQ™ platform for the early identification and optimization of developable candidates, alongside OneCyte’s single-cell technology to rapidly identify elite, high-producing clones. This creates a streamlined, flexible process designed to deliver high-performing cell lines with greater speed and confidence. Our goal is straightforward: to accelerate timelines, improve titers, and increase success rates for complex and difficult-to-express biologics. This partnership represents a significant step forward for biopharma teams working at the cutting edge of new modalities.